NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Devices · USD

Artivion, Inc. (AORT) Stock Analysis

Artivion, Inc. (AORT) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

AORT

$25.57

−$0.05 (−0.20%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AORT with… →

AORT Key Statistics

As of Sep 4, 2026
Trading
Open
$25.37
Previous Close
$25.62
Day's Range
25.18–25.69
52-Week Range
19.16–48.25
Volume
418.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.25
Valuation
Market Cap
$1.25B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
32.71
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.64
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.06
Financials (FY)
Revenue (FY)
$441.33M+13.59%
Net Income (FY)
$9.77M
Profit marginThe share of revenue left as profit after all costs and taxes.
−0.67%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.76M
1-Year Return
−41.93%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
739.07K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AORT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−43.94%
2025+59.53%
2024+59.90%
2023+47.52%
2022−40.44%
2021−13.81%
2020−12.85%
2019−4.55%
2018+48.20%
2017+0.00%
2016 (partial year)+33.54%

As of September 4, 2026.

AORT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$441.33M$9.77M2.2%
2024$388.54M−$13.36M−3.4%
2023$354.00M−$30.69M−8.7%
2022$313.79M−$19.19M−6.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$441.33M$284.23M$26.75M$9.77M2.2%
2024$388.54M$248.78M$38.87M−$13.36M−3.4%
2023$354.00M$229.18M−$8.51M−$30.69M−8.7%
2022$313.79M$202.52M$6.20M−$19.19M−6.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AORT Valuation vs Medical Devices Median

Median of 151 stocks
MetricAORTMedical Devices medianvs median
P/S ratio2.642.9811% below
Profit margin−0.67%−1.69%1.0 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Artivion, Inc. (AORT) carries a market capitalisation of $1.25B. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 1,800.

AORT last closed at $25.57 on September 4, 2026. That is −$0.05 (−0.20%) against the previous close. Over the past 52 weeks the price has ranged from $19.16 to $48.25. The latest close sits 33.46% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $441.33M. Against the prior fiscal year total of $388.54M, that is a change of +13.59%. Net income for the same year was $9.77M. The reported profit margin is −0.67%. That is 1 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are −0.06.

Across the 4 fiscal years on file, revenue moves from $313.79M in 2022 to $441.33M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 32.71. Measured against sales, the shares trade at 2.64 times revenue. On price-to-sales that is 11.15% below the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Over the trailing twelve months the price has returned −41.93%. Measured over 10 years, that is +4.65% a year compounded. The reported beta is 1.25. Daily returns over the trailing 10 years annualize to a volatility of 44.92%.

Growth & Income

The record shows no dividend for AORT.

So far in 2026 the price is −43.94%. Across the complete calendar years on file, 2024 returned +59.90% and 2022 returned −40.44%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Artivion, Inc. (AORT) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Artivion, Inc. AORT $1.25B —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Artivion, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Artivion, Inc.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Visit website →